Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.

Holthof LC, van der Horst HJ, van Hal-van Veen SE, Ruiter RWJ, Li F, Buijze M, Andersen MN, Yuan H, de Bruijn J, van de Donk NWCJ, Lokhorst HM, Zweegman S, Groen RWJ, Mutis T.

Haematologica. 2019 May 23. pii: haematol.2018.213314. doi: 10.3324/haematol.2018.213314. [Epub ahead of print]

2.

Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.

Drent E, Poels R, Ruiter R, van de Donk NWCJ, Zweegman S, Yuan H, de Bruijn J, Sadelain M, Lokhorst HM, Groen RWJ, Mutis T, Themeli M.

Clin Cancer Res. 2019 Jul 1;25(13):4014-4025. doi: 10.1158/1078-0432.CCR-18-2559. Epub 2019 Apr 12.

PMID:
30979735
3.

Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial.

Wester R, van der Holt B, Asselbergs E, Zweegman S, Kersten MJ, Vellenga E, van Marwijk Kooy M, de Weerdt O, Minnema M, Lonergan S, Palumbo A, Lokhorst H, Broijl A, Sonneveld P.

Haematologica. 2019 Apr 4. pii: haematol.2018.205476. doi: 10.3324/haematol.2018.205476. [Epub ahead of print]

4.

T Cells Specific for an Unconventional Natural Antigen Fail to Recognize Leukemic Cells.

Pont MJ, Oostvogels R, van Bergen CAM, van der Meijden ED, Honders MW, Bliss S, Jongsma MLM, Lokhorst HM, Falkenburg JHF, Mutis T, Griffioen M, Spaapen RM.

Cancer Immunol Res. 2019 May;7(5):797-804. doi: 10.1158/2326-6066.CIR-18-0137. Epub 2019 Mar 19.

PMID:
30890530
5.

Immunotherapy in myeloma: how far have we come?

Franssen LE, Mutis T, Lokhorst HM, van de Donk NWCJ.

Ther Adv Hematol. 2019 Jan 18;10:2040620718822660. doi: 10.1177/2040620718822660. eCollection 2019. Review.

6.

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.

Adams HC 3rd, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, Usmani SZ, Plesner T, Lonial S, Nijhof I, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK, Casneuf T.

Cytometry A. 2019 Mar;95(3):279-289. doi: 10.1002/cyto.a.23693. Epub 2018 Dec 11.

7.

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients.

Franssen LE, Nijhof IS, Bjorklund CC, Chiu H, Doorn R, van Velzen J, Emmelot M, van Kessel B, Levin MD, Bos GMJ, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Raymakers R, Sonneveld P, Zweegman S, Lokhorst HM, Thakurta A, Qian X, Mutis T, van de Donk NWCJ.

Oncotarget. 2018 Sep 21;9(74):34009-34021. doi: 10.18632/oncotarget.26131. eCollection 2018 Sep 21.

8.

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM.

Lancet Haematol. 2018 Oct;5(10):e479-e492. doi: 10.1016/S2352-3026(18)30149-2.

PMID:
30290905
9.

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.

Drent E, Poels R, Mulders MJ, van de Donk NWCJ, Themeli M, Lokhorst HM, Mutis T.

PLoS One. 2018 May 30;13(5):e0197349. doi: 10.1371/journal.pone.0197349. eCollection 2018.

10.

Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.

Vermeulen R, Saberi Hosnijeh F, Bodinier B, Portengen L, Liquet B, Garrido-Manriquez J, Lokhorst H, Bergdahl IA, Kyrtopoulos SA, Johansson AS, Georgiadis P, Melin B, Palli D, Krogh V, Panico S, Sacerdote C, Tumino R, Vineis P, Castagné R, Chadeau-Hyam M; EnviroGenoMarkers Consortium Consortium members, Botsivali M, Chatziioannou A, Valavanis I, Kleinjans JCS, de Kok TMCM, Keun HC, Athersuch TJ, Kelly R, Lenner P, Hallmans G, Stephanou EG, Myridakis A, Kogevinas M, Fazzo L, De Santis M, Comba P, Bendinelli B, Kiviranta H, Rantakokko P, Airaksinen R, Ruokojarvi P, Gilthorpe M, Fleming S, Fleming T, Tu YK, Lundh T, Chien KL, Chen WJ, Lee WC, Kate Hsiao C, Kuo PH, Hung H, Liao SF.

Int J Cancer. 2018 Sep 15;143(6):1335-1347. doi: 10.1002/ijc.31536. Epub 2018 Apr 26.

11.

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients.

Franssen LE, Nijhof IS, Couto S, Levin MD, Bos GMJ, Broijl A, Klein SK, Ren Y, Wang M, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Raymakers R, Leguit RJ, Sonneveld P, Zweegman S, Lokhorst H, Mutis T, Thakurta A, Qian X, van de Donk NWCJ.

Haematologica. 2018 Aug;103(8):e368-e371. doi: 10.3324/haematol.2017.186601. Epub 2018 Mar 15. No abstract available.

12.

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.

Frerichs KA, Nagy NA, Lindenbergh PL, Bosman P, Marin Soto J, Broekmans M, Groen RWJ, Themeli M, Nieuwenhuis L, Stege C, Nijhof IS, Mutis T, Zweegman S, Lokhorst HM, van de Donk NWCJ.

Expert Rev Clin Immunol. 2018 Mar;14(3):197-206. doi: 10.1080/1744666X.2018.1443809. Epub 2018 Feb 28. Review.

PMID:
29465271
13.

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

van de Donk NWCJ, Casneuf T, Di Cara A, Parren PW, Zweegman S, van Kessel B, Lokhorst HM, Usmani SZ, Lonial S, Richardson PG, Chiu C, Mutis T, Nijhof IS, Sasser AK.

Br J Haematol. 2019 Feb;184(3):475-479. doi: 10.1111/bjh.15122. Epub 2018 Feb 7. No abstract available.

PMID:
29411874
14.

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.

Casneuf T, Xu XS, Adams HC 3rd, Axel AE, Chiu C, Khan I, Ahmadi T, Yan X, Lonial S, Plesner T, Lokhorst HM, van de Donk NWCJ, Clemens PL, Sasser AK.

Blood Adv. 2017 Oct 24;1(23):2105-2114. doi: 10.1182/bloodadvances.2017006866. eCollection 2017 Oct 24.

15.

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.

Nijhof IS, van de Donk NWCJ, Zweegman S, Lokhorst HM.

Drugs. 2018 Jan;78(1):19-37. doi: 10.1007/s40265-017-0841-y. Review.

16.

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

Krejcik J, Frerichs KA, Nijhof IS, van Kessel B, van Velzen JF, Bloem AC, Broekmans MEC, Zweegman S, van Meerloo J, Musters RJP, Poddighe PJ, Groen RWJ, Chiu C, Plesner T, Lokhorst HM, Sasser AK, Mutis T, van de Donk NWCJ.

Clin Cancer Res. 2017 Dec 15;23(24):7498-7511. doi: 10.1158/1078-0432.CCR-17-2027. Epub 2017 Oct 12.

17.

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.

Yan X, Clemens PL, Puchalski T, Lonial S, Lokhorst H, Voorhees PM, Usmani S, Richardson PG, Plesner T, Liu K, Orlowski RZ, Losic N, Jansson R, Ahmadi T, Lantz K, Ruixo JJP, Zhou H, Xu XS.

Clin Pharmacokinet. 2018 Apr;57(4):529-538. doi: 10.1007/s40262-017-0598-1.

18.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P.

Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.

PMID:
28761118
19.

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM.

Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.

PMID:
28620163
20.

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma.

Franssen LE, Roeven MWH, Hobo W, Doorn R, Oostvogels R, Falkenburg JHF, van de Donk NW, Kester MGD, Fredrix H, Westinga K, Slaper-Cortenbach I, Spierings E, Kersten MJ, Dolstra H, Mutis T, Schaap N, Lokhorst HM.

Bone Marrow Transplant. 2017 Oct;52(10):1378-1383. doi: 10.1038/bmt.2017.118. Epub 2017 Jun 5.

PMID:
28581468
21.

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.

Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J, Martens ACM, Zweegman S, van de Donk NWCJ, Groen RWJ, Lokhorst HM, Mutis T.

Mol Ther. 2017 Aug 2;25(8):1946-1958. doi: 10.1016/j.ymthe.2017.04.024. Epub 2017 May 13.

22.

A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.

Franken B, van de Donk NW, Cloos JC, Zweegman S, Lokhorst HM.

Ther Adv Hematol. 2016 Dec;7(6):330-344. Epub 2016 Sep 13. Review.

23.

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.

Clemens PL, Yan X, Lokhorst HM, Lonial S, Losic N, Khan I, Jansson R, Ahmadi T, Lantz K, Zhou H, Puchalski T, Xu XS.

Clin Pharmacokinet. 2017 Aug;56(8):915-924. doi: 10.1007/s40262-016-0477-1.

24.

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma.

Xu XS, Yan X, Puchalski T, Lonial S, Lokhorst HM, Voorhees PM, Plesner T, Liu K, Khan I, Jansson R, Ahmadi T, Ruixo JP, Zhou H, Clemens PL.

Clin Pharmacol Ther. 2017 Jun;101(6):721-724. doi: 10.1002/cpt.577. Epub 2017 Feb 13.

25.

Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients.

Oostvogels R, Kneppers E, Minnema MC, Doorn RC, Franssen LE, Aarts T, Emmelot ME, Spierings E, Slaper-Cortenbach I, Westinga K, Goulmy E, Lokhorst HM, Mutis T.

Bone Marrow Transplant. 2017 Feb;52(2):228-237. doi: 10.1038/bmt.2016.250. Epub 2016 Nov 14.

PMID:
27841858
26.

Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.

Garderet L, Cook G, Auner HW, Bruno B, Lokhorst H, Perez-Simon JA, Sahebi F, Scheid C, Morris C, van Biezen A, Sobh M, Michallet M, Gahrton G, Schönland S, Kröger N.

Leuk Lymphoma. 2017 Apr;58(4):797-808. doi: 10.1080/10428194.2016.1228926. Epub 2016 Sep 21.

27.

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.

Nijhof IS, Franssen LE, Levin MD, Bos GMJ, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Ypma PF, Raymakers R, van Spronsen DJ, Westerweel PE, Oostvogels R, van Velzen J, van Kessel B, Mutis T, Sonneveld P, Zweegman S, Lokhorst HM, van de Donk NWCJ.

Blood. 2016 Nov 10;128(19):2297-2306. doi: 10.1182/blood-2016-07-729236. Epub 2016 Sep 19.

28.

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG.

Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.

29.

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW.

Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15.

30.

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.

Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK.

Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24.

31.

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H.

Blood. 2016 Jul 7;128(1):37-44. doi: 10.1182/blood-2016-03-705210. Epub 2016 May 23.

32.

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Moreau P, van de Donk NW, Miguel JS, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Mateos MV.

Drugs. 2016 Jun;76(9):989-990. No abstract available.

PMID:
27206917
33.

Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses.

de Haart SJ, Willems SM, Mutis T, Koudijs MJ, van Blokland MT, Lokhorst HM, de Weger RA, Minnema MC.

Blood Cancer J. 2016 May 20;6:e426. doi: 10.1038/bcj.2016.35. No abstract available.

34.

Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

van de Donk NW, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S.

Int J Lab Hematol. 2016 May;38 Suppl 1:110-22. doi: 10.1111/ijlh.12504. Epub 2016 May 9. Review.

PMID:
27161311
35.

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.

de Haart SJ, Holthof L, Noort WA, Minnema MC, Emmelot ME, Aarts-Riemens T, Doshi P, Sasser K, Yuan H, de Bruijn J, Martens AC, van de Donk NW, Lokhorst HM, Groen RW, Mutis T.

Haematologica. 2016 Aug;101(8):e339-42. doi: 10.3324/haematol.2015.139667. Epub 2016 May 5. No abstract available.

36.

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Moreau P, van de Donk NW, San Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Mateos MV.

Drugs. 2016 May;76(8):853-67. doi: 10.1007/s40265-016-0573-4. Review. Erratum in: Drugs. 2016 Jun;76(9):989-90.

PMID:
27113582
37.

Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution.

Franssen LE, Raymakers RA, Buijs A, Schmitz MF, van Dorp S, Mutis T, Lokhorst HM, van de Donk NW.

Eur J Haematol. 2016 Nov;97(5):479-488. doi: 10.1111/ejh.12758. Epub 2016 May 3.

PMID:
27028304
38.

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

van de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, Lokhorst HM, Parren PW.

Immunol Rev. 2016 Mar;270(1):95-112. doi: 10.1111/imr.12389. Review.

39.

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

Drent E, Groen RW, Noort WA, Themeli M, Lammerts van Bueren JJ, Parren PW, Kuball J, Sebestyen Z, Yuan H, de Bruijn J, van de Donk NW, Martens AC, Lokhorst HM, Mutis T.

Haematologica. 2016 May;101(5):616-25. doi: 10.3324/haematol.2015.137620. Epub 2016 Feb 8.

40.

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.

Broijl A, Kersten MJ, Alemayehu WG, Levin MD, de Weerdt O, Vellenga E, Meijer E, Wittebol S, Tanis BC, Cornelisse PB, Stevens-Kroef M, Bos GM, Wijermans PW, Lokhorst H, Sonneveld P.

Haematologica. 2016 Apr;101(4):e149-52. doi: 10.3324/haematol.2015.132431. Epub 2015 Dec 11. No abstract available.

41.

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

van de Donk NW, Moreau P, Plesner T, Palumbo A, Gay F, Laubach JP, Malavasi F, Avet-Loiseau H, Mateos MV, Sonneveld P, Lokhorst HM, Richardson PG.

Blood. 2016 Feb 11;127(6):681-95. doi: 10.1182/blood-2015-10-646810. Epub 2015 Dec 2. Review.

42.

Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives.

Oostvogels R, Lokhorst HM, Mutis T.

Bone Marrow Transplant. 2016 Feb;51(2):163-71. doi: 10.1038/bmt.2015.256. Epub 2015 Oct 26. Review.

PMID:
26501766
43.

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.

Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-2051. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30.

44.

Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.

Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P.

Haematologica. 2015 Dec;100(12):e508-10. doi: 10.3324/haematol.2015.128728. Epub 2015 Sep 4. No abstract available.

45.

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.

Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, El Jarari L, van Beers EH, Mulligan G, Avet-Loiseau H, Gregory WM, Morgan G, Goldschmidt H, Lokhorst HM, Sonneveld P.

Blood. 2015 Oct 22;126(17):1996-2004. doi: 10.1182/blood-2015-05-644039. Epub 2015 Sep 1.

46.

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG.

N Engl J Med. 2015 Sep 24;373(13):1207-19. doi: 10.1056/NEJMoa1506348. Epub 2015 Aug 26.

47.

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P.

J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.

48.

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.

Nijhof IS, Groen RW, Lokhorst HM, van Kessel B, Bloem AC, van Velzen J, de Jong-Korlaar R, Yuan H, Noort WA, Klein SK, Martens AC, Doshi P, Sasser K, Mutis T, van de Donk NW.

Leukemia. 2015 Oct;29(10):2039-49. doi: 10.1038/leu.2015.123. Epub 2015 May 15.

PMID:
25975191
49.

The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs.

Franssen LE, van de Donk NW, Emmelot ME, Roeven MW, Schaap N, Dolstra H, Hobo W, Lokhorst HM, Mutis T.

Bone Marrow Transplant. 2015 Jun;50(6):822-8. doi: 10.1038/bmt.2015.48. Epub 2015 Mar 23.

PMID:
25798669
50.

Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.

Hazenberg BP, Croockewit A, van der Holt B, Zweegman S, Bos GM, Delforge M, Raymakers RA, Sonneveld P, Vellenga E, Wijermans PW, von dem Borne PA, van Oers MH, de Weerdt O, Spoelstra FM, Lokhorst HM; Dutch-Belgian Cooperative Trial Group for Hematology Oncology.

Haematologica. 2015 May;100(5):677-82. doi: 10.3324/haematol.2014.119198. Epub 2015 Feb 6.

Supplemental Content

Loading ...
Support Center